Vanguard Group Inc. lifted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 235.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,327,864 shares of the company's stock after purchasing an additional 3,738,616 shares during the quarter. Vanguard Group Inc. owned 2.85% of Taysha Gene Therapies worth $16,836,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently modified their holdings of TSHA. Capital Investment Advisors LLC bought a new position in Taysha Gene Therapies in the 3rd quarter valued at about $32,000. Maven Securities LTD acquired a new position in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $34,000. AQR Capital Management LLC acquired a new position in shares of Taysha Gene Therapies during the second quarter valued at approximately $38,000. Lee Financial Co bought a new stake in Taysha Gene Therapies during the third quarter worth approximately $63,000. Finally, XTX Topco Ltd acquired a new stake in Taysha Gene Therapies in the first quarter worth approximately $68,000. Institutional investors own 77.70% of the company's stock.
Analysts Set New Price Targets
A number of research firms have recently commented on TSHA. Canaccord Genuity Group reissued a "buy" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Piper Sandler began coverage on shares of Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an "overweight" rating and a $9.00 price target for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Chardan Capital boosted their target price on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a "buy" rating in a report on Thursday, March 21st. Finally, JMP Securities restated a "market outperform" rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $6.88.
Check Out Our Latest Report on Taysha Gene Therapies
Taysha Gene Therapies Trading Down 9.5 %
NASDAQ TSHA traded down $0.28 on Monday, hitting $2.66. 2,029,063 shares of the stock were exchanged, compared to its average volume of 2,713,532. The company's 50-day moving average price is $2.47 and its two-hundred day moving average price is $2.11. The company has a market capitalization of $497.47 million, a price-to-earnings ratio of -4.13 and a beta of 0.29. Taysha Gene Therapies, Inc. has a 52-week low of $0.50 and a 52-week high of $3.89. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The company had revenue of $3.60 million during the quarter, compared to analysts' expectations of $4.75 million. Research analysts predict that Taysha Gene Therapies, Inc. will post -0.39 EPS for the current year.
Taysha Gene Therapies Profile
(
Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Further Reading
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
